Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
| 対象疾患 | Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Malignant Mixed Mesodermal Tumor |
|---|---|
| 相 | 第2相 |
| スポンサー | National Cancer Institute (NCI) |
| ステータス | 実施中（募集終了） |
| 参加者数 | 124 名 |
| 介入（薬剤） | Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration |
| 開始日 | 2014年7月21日 |
| 完了日 | 2022年2月3日 |
| 結果公開日 | 2023年9月8日 |
概要
This randomized phase II clinical trial studies how well gemcitabine hydrochloride and WEE1 inhibitor MK-1775 work compared to gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of time. Gemcitabine hydrochloride may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA, molecules that contain instructions for the proper development and functioning of cells), which in turn stops the tumor from growing. The protein WEE1 may help to repair the damaged tumor cells, so the tumor continues to grow. WEE1 inhibitor MK-1775 may block the WEE1 protein activity and may increase the effectiveness of gemcitabine hydrochloride by preventing the WEE1 protein from repairing damaged tumor cells without causing harm to normal cells. It is not yet known whether gemcitabine hydrochloride with or without WEE1 inhibitor MK-1775 may be an effective treatment for recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Progression Free Survival
| Arm I (WEE1 Inhibitor AZD1775, Gemcitabine Hydrochloride) | 4.6 months |
|---|---|
| Arm II (Placebo, Gemcitabine Hydrochloride) | 3.0 months |
| Arm III (Exploratory WEE1 Inhibitor AZD1775, Gemcitabine) | 5.3 months |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)